GFAP and myeloid sarcoma: Furthermore, in 3 out of 4 protocols, GFAP levels were assessed in serum; it is important to consider that almost all findings about GFAP levels were obtained in the CSF of MS patients, and such findings still need to be adequately replicated in serum.